Foglia B, Sutti S, Cannito S, Rosso C, Maggiora M, Casalino A
Front Immunol. 2024; 15:1342404.
PMID: 38469298
PMC: 10925642.
DOI: 10.3389/fimmu.2024.1342404.
Morine Y, Utsunomiya T, Yamanaka-Okumura H, Saito Y, Yamada S, Ikemoto T
Oncotarget. 2022; 13:1286-1298.
PMID: 36441784
PMC: 11623405.
DOI: 10.18632/oncotarget.28306.
Li X, Cheng L, Li C, Hu X, Hu X, Tan L
J Clin Transl Hepatol. 2022; 10(1):63-71.
PMID: 35233374
PMC: 8845145.
DOI: 10.14218/JCTH.2021.00023.
Maira G, Foglia B, Napione L, Turato C, Maggiora M, Sutti S
J Pathol. 2022; 257(1):82-95.
PMID: 35064579
PMC: 9315146.
DOI: 10.1002/path.5871.
Raja A, Haq F
J Cancer Res Clin Oncol. 2021; 148(1):15-29.
PMID: 34623518
DOI: 10.1007/s00432-021-03826-w.
Hepatocellular carcinoma as a complication of Niemann-Pick disease type C1.
Rodriguez-Gil J, Bianconi S, Farhat N, Kleiner D, Nelson M, Porter F
Am J Med Genet A. 2021; 185(10):3111-3117.
PMID: 34138521
PMC: 8446311.
DOI: 10.1002/ajmg.a.62382.
Inflammatory Mechanisms of HCC Development.
Refolo M, Messa C, Guerra V, Carr B, DAlessandro R
Cancers (Basel). 2020; 12(3).
PMID: 32164265
PMC: 7139884.
DOI: 10.3390/cancers12030641.
Identification Of Novel lncRNAs For Detection Of HBV-Associated Hepatocellular Carcinoma.
Li Y, Chen X, Huang H, Li G, Liao L, Yuan T
Onco Targets Ther. 2019; 12:10199-10211.
PMID: 31819509
PMC: 6885655.
DOI: 10.2147/OTT.S230377.
Comprehensive analysis of transcriptome profiles in hepatocellular carcinoma.
Jin Y, Lee W, Toh S, Tennakoon C, Toh H, Chow P
J Transl Med. 2019; 17(1):273.
PMID: 31429776
PMC: 6701074.
DOI: 10.1186/s12967-019-2025-x.
The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells.
Wang J, Wei H, Huang Y, Chen D, Zeng G, Lian Y
Aging (Albany NY). 2019; 11(15):5769-5785.
PMID: 31409760
PMC: 6710066.
DOI: 10.18632/aging.102165.
Role of Allelic Imbalance in Predicting Hepatocellular Carcinoma (HCC) Recurrence Risk After Liver Transplant.
Pagano D, Barbera F, Conaldi P, Seidita A, DI Francesco F, Di Carlo D
Ann Transplant. 2019; 24:223-233.
PMID: 31015392
PMC: 6500106.
DOI: 10.12659/AOT.913692.
Systemic therapy for hepatocellular carcinoma: why do we keep failing?.
Kim B, Park J
Hepat Oncol. 2018; 1(4):355-358.
PMID: 30190969
PMC: 6095331.
DOI: 10.2217/hep.14.23.
Integrated analysis of the impact of age on genetic and clinical aspects of hepatocellular carcinoma.
Atyah M, Yin Y, Zhou C, Zhou Q, Chen W, Dong Q
Aging (Albany NY). 2018; 10(8):2079-2097.
PMID: 30125264
PMC: 6128442.
DOI: 10.18632/aging.101531.
Transcriptome profiling of HepG2 cells exposed to the flame retardant 9,10-dihydro-9-oxa-10-phosphaphenanthrene 10-oxide (DOPO).
Krivoshiev B, Beemster G, Sprangers K, Cuypers B, Laukens K, Blust R
Toxicol Res (Camb). 2018; 7(3):492-502.
PMID: 30090599
PMC: 6060682.
DOI: 10.1039/c8tx00006a.
Hepatocellular carcinoma-related cyclin D1 is selectively regulated by autophagy degradation system.
Wu S, Lan S, Wu S, Chiu Y, Lin X, Su I
Hepatology. 2018; 68(1):141-154.
PMID: 29328502
PMC: 6055810.
DOI: 10.1002/hep.29781.
Insertional Mutagenesis in Mice Identifies Drivers of Steatosis-Associated Hepatic Tumors.
Tschida B, Temiz N, Kuka T, Lee L, Riordan J, Tierrablanca C
Cancer Res. 2017; 77(23):6576-6588.
PMID: 28993411
PMC: 5712258.
DOI: 10.1158/0008-5472.CAN-17-2281.
Conditional Survival Analysis Demonstrates that Recurrence Risk of Surgically Treated Hepatocellular Carcinoma Evolves with Time.
Park Y, Song S, Kim B, Park S, Lee J, Lim S
J Gastrointest Surg. 2017; 21(8):1237-1244.
PMID: 28536805
PMC: 5517592.
DOI: 10.1007/s11605-017-3437-7.
Disease monitoring of hepatocellular carcinoma through metabolomics.
Fitian A, Cabrera R
World J Hepatol. 2017; 9(1):1-17.
PMID: 28105254
PMC: 5220267.
DOI: 10.4254/wjh.v9.i1.1.
Accumulation of Deleterious Passenger Mutations Is Associated with the Progression of Hepatocellular Carcinoma.
Budzinska M, Tu T, dAvigdor W, McCaughan G, Luciani F, Shackel N
PLoS One. 2016; 11(9):e0162586.
PMID: 27631787
PMC: 5025244.
DOI: 10.1371/journal.pone.0162586.
Identification of New Players in Hepatocarcinogenesis: Limits and Opportunities of Using Tissue Microarray (TMA).
Quagliata L, Schlageter M, Quintavalle C, Tornillo L, Terracciano L
Microarrays (Basel). 2016; 3(2):91-102.
PMID: 27600338
PMC: 5003443.
DOI: 10.3390/microarrays3020091.